{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:48:08Z","timestamp":1790128088529,"version":"4.0.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","award":["2022 International Prize for Scientific Research Arrigo Recordati"],"award-info":[{"award-number":["2022 International Prize for Scientific Research Arrigo Recordati"]}],"id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","award":["10th Edition"],"award-info":[{"award-number":["10th Edition"]}],"id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior, due to their clinical course, local invasive growth, resistance to conventional therapies and the risk of disease progression. Recent studies on tumor microenvironment (TME) provided new knowledge on the biology of these neoplasia, that may explain the different phenotypes of these tumors and suggest new biomarkers able to predict the prognosis and the treatment outcome. The identification of molecular markers that act as targets for biological therapies may open new perspectives in the medical treatments of aggressive pituitary tumors.<\/jats:p><jats:p>In this paper, we will review data of TME and target therapies in somatotropinomas.<\/jats:p>","DOI":"10.1007\/s11154-022-09782-1","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T04:42:41Z","timestamp":1674189761000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The immune microenviroment in somatotropinomas: from biology to personalized and target therapy"],"prefix":"10.1007","volume":"24","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9916-0669","authenticated-orcid":false,"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"1","key":"9782_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1\u201324. https:\/\/doi.org\/10.1530\/EJE-17-0796.","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"9782_CR2","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24(4):C5\u20138. https:\/\/doi.org\/10.1530\/ERC-17-0004.","journal-title":"Endocr Relat Cancer."},{"key":"9782_CR3","unstructured":"WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/53."},{"issue":"3","key":"9782_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265\u201376. https:\/\/doi.org\/10.1530\/EJE-17-0933.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"9782_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-020-09562-9","volume":"21","author":"J Trouillas","year":"2020","unstructured":"Trouillas J, Jaffrain-Rea M-L, Vasiljevic A, et al. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician\u2019s questions. Rev Endocr Metab Disord. 2020;21(2):243\u201351. https:\/\/doi.org\/10.1007\/s11154-020-09562-9.","journal-title":"Rev Endocr Metab Disord."},{"issue":"12","key":"9782_CR6","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, et al. Successful Mortality Reduction and Control of Comorbidities in Patients With Acromegaly Followed at a Highly Specialized Multidisciplinary Clinic. J Clin Endocrinol Metab. 2014;99(12):4438\u201346. https:\/\/doi.org\/10.1210\/jc.2014-2670.","journal-title":"J Clin Endocrinol Metab."},{"key":"9782_CR7","unstructured":"DeLellis RA, Lloyd RV, Heitz PU EC. No Title. 3rd edn IARC. 2004;3rd edn:10\u201313."},{"issue":"2","key":"9782_CR8","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","volume":"12","author":"J Trouillas","year":"2020","unstructured":"Trouillas J, Jaffrain-Rea M-L, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020;12(2):514. https:\/\/doi.org\/10.3390\/cancers12020514.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"9782_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17(11):671\u201384. https:\/\/doi.org\/10.1038\/s41574-021-00550-w.","journal-title":"Nat Rev Endocrinol."},{"issue":"1","key":"9782_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou M, Villa C, Armignacco R, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020;37(1):123-134.e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002.","journal-title":"Cancer Cell."},{"issue":"4","key":"9782_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cancers12041012","volume":"12","author":"MD Ilie","year":"2020","unstructured":"Ilie MD, Vasiljevic A, Louvet C, Jouanneau E, Raverot G. Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. Cancers (Basel). 2020;12(4):1012. https:\/\/doi.org\/10.3390\/cancers12041012.","journal-title":"Cancers (Basel)."},{"key":"9782_CR12","doi-asserted-by":"publisher","unstructured":"Ilie, Lasolle, Raverot. Emerging and Novel Treatments for Pituitary Tumors. J Clin Med. 2019;8(8):1107. https:\/\/doi.org\/10.3390\/jcm8081107","DOI":"10.3390\/jcm8081107"},{"key":"9782_CR13","doi-asserted-by":"publisher","unstructured":"Marques P, Grossman AB, Korbonits M. The tumour microenvironment of pituitary neuroendocrine tumours. Front Neuroendocrinol. 2020;58:100852. https:\/\/doi.org\/10.1016\/j.yfrne.2020.100852","DOI":"10.1016\/j.yfrne.2020.100852"},{"issue":"1","key":"9782_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13578-020-00488-y","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Gu C, Song Q, et al. Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma. Cell Biosci. 2020;10(1):127. https:\/\/doi.org\/10.1186\/s13578-020-00488-y.","journal-title":"Cell Biosci."},{"key":"9782_CR15","doi-asserted-by":"publisher","unstructured":"Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The microenvironment of pituitary tumors-biological and therapeutic implications. Cancers (Basel). 2019;11(10). https:\/\/doi.org\/10.3390\/cancers11101605","DOI":"10.3390\/cancers11101605"},{"issue":"1\u20132","key":"9782_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.mce.2012.04.005","volume":"361","author":"V Touskova","year":"2012","unstructured":"Touskova V, Trachta P, Kavalkova P, et al. Serum concentrations and tissue expression of components of insulin-like growth factor-axis in females with type 2 diabetes mellitus and obesity: The influence of very-low-calorie diet. Mol Cell Endocrinol. 2012;361(1\u20132):172\u20138. https:\/\/doi.org\/10.1016\/j.mce.2012.04.005.","journal-title":"Mol Cell Endocrinol."},{"issue":"2","key":"9782_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1530\/JME-17-0062","volume":"59","author":"TLC Wolters","year":"2017","unstructured":"Wolters TLC, Netea MG, Hermus ARMM, Smit JWA, Netea-Maier RT. IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK. J Mol Endocrinol. 2017;59(2):129\u201339. https:\/\/doi.org\/10.1530\/JME-17-0062.","journal-title":"J Mol Endocrinol."},{"issue":"2","key":"9782_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11154-021-09649-x","volume":"22","author":"G Tulipano","year":"2021","unstructured":"Tulipano G, Giustina A. Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. Rev Endocr Metab Disord. 2021;22(2):147\u201360. https:\/\/doi.org\/10.1007\/s11154-021-09649-x.","journal-title":"Rev Endocr Metab Disord."},{"issue":"3","key":"9782_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","volume":"26","author":"JQ Lu","year":"2015","unstructured":"Lu JQ, Adam B, Jack AS, Lam A, Broad RW, Chik CL. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas. Endocr Pathol. 2015;26(3):263\u201372. https:\/\/doi.org\/10.1007\/s12022-015-9383-6.","journal-title":"Endocr Pathol."},{"issue":"3","key":"9782_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-020-01114-3","volume":"24","author":"Y Mei","year":"2021","unstructured":"Mei Y, Bi WL, Agolia J, et al. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary. 2021;24(3):359\u201373. https:\/\/doi.org\/10.1007\/s11102-020-01114-3.","journal-title":"Pituitary."},{"issue":"3","key":"9782_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11060-020-03636-z","volume":"149","author":"W Zhou","year":"2020","unstructured":"Zhou W, Zhang C, Zhang D, et al. Comprehensive analysis of the immunological landscape of pituitary adenomas: implications of immunotherapy for pituitary adenomas. J Neurooncol. 2020;149(3):473\u201387. https:\/\/doi.org\/10.1007\/s11060-020-03636-z.","journal-title":"J Neurooncol."},{"issue":"9","key":"9782_CR22","doi-asserted-by":"publisher","first-page":"E3207","DOI":"10.1210\/clinem\/dgaa449","volume":"105","author":"Z Wang","year":"2020","unstructured":"Wang Z, Guo X, Gao L, et al. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. J Clin Endocrinol Metab. 2020;105(9):E3207\u201323. https:\/\/doi.org\/10.1210\/clinem\/dgaa449.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"9782_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","volume":"7","author":"P Marques","year":"2019","unstructured":"Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun. 2019;7(1):172. https:\/\/doi.org\/10.1186\/s40478-019-0830-3.","journal-title":"Acta Neuropathol Commun."},{"issue":"6","key":"9782_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00418-008-0527-3","volume":"130","author":"M-A Bitoux","year":"2008","unstructured":"Bitoux M-A, Stamenkovic I. Tumor-host interactions: the role of inflammation. Histochem Cell Biol. 2008;130(6):1079\u201390. https:\/\/doi.org\/10.1007\/s00418-008-0527-3.","journal-title":"Histochem Cell Biol."},{"issue":"23","key":"9782_CR25","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591\u20136. https:\/\/doi.org\/10.1242\/jcs.116392.","journal-title":"J Cell Sci."},{"issue":"1","key":"9782_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui L, Chen Y. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 2015;368(1):7\u201313. https:\/\/doi.org\/10.1016\/j.canlet.2015.07.039.","journal-title":"Cancer Lett."},{"issue":"12","key":"9782_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717\u201334. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101.","journal-title":"Nat Rev Clin Oncol."},{"issue":"3","key":"9782_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00005-008-0018-1","volume":"56","author":"A Kosmaczewska","year":"2008","unstructured":"Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 2008;56(3):181\u201391. https:\/\/doi.org\/10.1007\/s00005-008-0018-1.","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"9782_CR29","unstructured":"Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19053167."},{"issue":"3","key":"9782_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","volume":"67","author":"D Iacovazzo","year":"2020","unstructured":"Iacovazzo D, Chiloiro S, Carlsen E, et al. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2020;67(3):651\u20138. https:\/\/doi.org\/10.1007\/s12020-019-02145-y.","journal-title":"Endocrine."},{"key":"9782_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2021.785050","volume":"12","author":"C Han","year":"2021","unstructured":"Han C, Lin S, Lu X, Xue L, Wu ZB. Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches. Front Endocrinol (Lausanne). 2021;12:1\u201310. https:\/\/doi.org\/10.3389\/fendo.2021.785050.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"9782_CR32","doi-asserted-by":"publisher","unstructured":"Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol. 2021;893:173819. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173819","DOI":"10.1016\/j.ejphar.2020.173819"},{"issue":"2","key":"9782_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1172\/JCI123027","volume":"129","author":"N Liu","year":"2019","unstructured":"Liu N, Luo J, Kuang D, et al. Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2\u03b1\u2013mediated tumor progression. J Clin Invest. 2019;129(2):631\u201346. https:\/\/doi.org\/10.1172\/JCI123027.","journal-title":"J Clin Invest."},{"issue":"8","key":"9782_CR34","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.7150\/THNO.53749","volume":"11","author":"A Zhang","year":"2021","unstructured":"Zhang A, Xu Y, Xu H, et al. Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics. 2021;11(8):3839\u201352. https:\/\/doi.org\/10.7150\/THNO.53749.","journal-title":"Theranostics."},{"key":"9782_CR35","doi-asserted-by":"publisher","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L De. Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best Pract Res Clin Endocrinol Metab. 2022. https:\/\/doi.org\/10.1016\/j.beem.2022.101684","DOI":"10.1016\/j.beem.2022.101684"},{"issue":"1","key":"9782_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje.1.01949","volume":"153","author":"W Allaerts","year":"2005","unstructured":"Allaerts W, Vankelecom H. History and perspectives of pituitary folliculo-stellate cell research. Eur J Endocrinol. 2005;153(1):1\u201312. https:\/\/doi.org\/10.1530\/eje.1.01949.","journal-title":"Eur J Endocrinol."},{"key":"9782_CR37","doi-asserted-by":"publisher","unstructured":"Denef C. Paracrinicity: the story of thirty years of cellular pituitary crosstalk. J Neuroendocrinol. 2007;ja(ja):070927052250003. https:\/\/doi.org\/10.1111\/j.1365-2826.2007.01616.x","DOI":"10.1111\/j.1365-2826.2007.01616.x"},{"issue":"1","key":"9782_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/en.2004-1269","volume":"146","author":"M Herkenham","year":"2005","unstructured":"Herkenham M. Folliculo-Stellate (FS) Cells of the Anterior Pituitary Mediate Interactions between the Endocrine and Immune Systems. Endocrinology. 2005;146(1):33\u20134. https:\/\/doi.org\/10.1210\/en.2004-1269.","journal-title":"Endocrinology."},{"issue":"3","key":"9782_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0344-0338(99)80026-0","volume":"195","author":"D Voit","year":"1999","unstructured":"Voit D, Saeger W, L\u00fcdecke DK. Folliculo-stellate Cells in Pituitary Adenomas of Patients with Acromegaly. Pathol - Res Pract. 1999;195(3):143\u20137. https:\/\/doi.org\/10.1016\/S0344-0338(99)80026-0.","journal-title":"Pathol - Res Pract."},{"issue":"3","key":"9782_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791\u20139. https:\/\/doi.org\/10.1210\/jc.2013-2480.","journal-title":"J Clin Endocrinol Metab."},{"issue":"February","key":"9782_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00931","volume":"10","author":"M Gadelha","year":"2020","unstructured":"Gadelha M, Bex M, Colao A, et al. Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Front Endocrinol (Lausanne). 2020;10(February):1\u201310. https:\/\/doi.org\/10.3389\/fendo.2019.00931.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"9782_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response. Eur J Endocrinol. 2021;184(2):217\u201329. https:\/\/doi.org\/10.1530\/EJE-20-0767.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"9782_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ib\u00e1\u00f1ez-Costa","year":"2016","unstructured":"Ib\u00e1\u00f1ez-Costa A, Rivero-Cort\u00e9s E, V\u00e1zquez-Borrego MC, et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol. 2016;231(2):135\u201345. https:\/\/doi.org\/10.1530\/JOE-16-0332.","journal-title":"J Endocrinol."},{"issue":"6","key":"9782_CR44","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE, et al. In vitro head-to-head comparison between octreotide and pasireotide in gh-secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102(6):2009\u201318. https:\/\/doi.org\/10.1210\/jc.2017-00135.","journal-title":"J Clin Endocrinol Metab."},{"issue":"December","key":"9782_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.608422","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020;11(December):1\u20139. https:\/\/doi.org\/10.3389\/fendo.2020.608422.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"9782_CR46","doi-asserted-by":"publisher","unstructured":"Wei SC, Sharma R, Anang N-AAS, et al. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. 2019;50(4):1084-1098.e10. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.004","DOI":"10.1016\/j.immuni.2019.03.004"},{"issue":"12","key":"9782_CR47","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to Cytotoxic T-Lymphocyte\u2013Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol. 2016;186(12):3225\u201335. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020.","journal-title":"Am J Pathol."},{"issue":"8","key":"9782_CR48","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","volume":"75","author":"Z Sun","year":"2015","unstructured":"Sun Z, Fourcade J, Pagliano O, et al. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015;75(8):1635\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3016.","journal-title":"Cancer Res."},{"issue":"4","key":"9782_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895\u2013904. https:\/\/doi.org\/10.1084\/jem.20160801.","journal-title":"J Exp Med."},{"issue":"3","key":"9782_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2020.12.026","volume":"84","author":"DM Weiner","year":"2021","unstructured":"Weiner DM, Durgin JS, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches. J Am Acad Dermatol. 2021;84(3):597\u2013604. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.026.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"9782_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","volume":"33","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Milardi D, De Marinis L, Pontecorvi A. The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol Metab. 2022;33(2):87\u2013104. https:\/\/doi.org\/10.1016\/j.tem.2021.10.009.","journal-title":"Trends Endocrinol Metab."},{"issue":"5","key":"9782_CR52","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-18-3486","volume":"26","author":"HR Kemeny","year":"2020","unstructured":"Kemeny HR, Elsamadicy AA, Harrison Farber S, et al. Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease. Clin Cancer Res. 2020;26(5):1141\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3486.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"9782_CR53","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-20-0151","volume":"184","author":"B Sol","year":"2021","unstructured":"Sol B, de Filette JMK, Awada G, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol. 2021;184(1):K1\u20135. https:\/\/doi.org\/10.1530\/EJE-20-0151.","journal-title":"Eur J Endocrinol."},{"issue":"47","key":"9782_CR54","doi-asserted-by":"publisher","first-page":"76565","DOI":"10.18632\/oncotarget.12088","volume":"7","author":"Y Mei","year":"2016","unstructured":"Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016;7(47):76565\u201376. https:\/\/doi.org\/10.18632\/oncotarget.12088.","journal-title":"Oncotarget."},{"key":"9782_CR55","doi-asserted-by":"publisher","unstructured":"Wang PF, Wang TJ, Yang YK, et al. The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol. 2018;139(1):89-95. https:\/\/doi.org\/10.1007\/s11060-018-2844-2","DOI":"10.1007\/s11060-018-2844-2"},{"issue":"3","key":"9782_CR56","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12020-020-02478-z","volume":"70","author":"P Marques","year":"2020","unstructured":"Marques P, Barry S, Carlsen E, et al. The role of the tumour microenvironment in the angiogenesis of pituitary tumours. Endocrine. 2020;70(3):593\u2013606. https:\/\/doi.org\/10.1007\/s12020-020-02478-z.","journal-title":"Endocrine."},{"issue":"6","key":"9782_CR57","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.mehy.2013.03.011","volume":"80","author":"L Qiu","year":"2013","unstructured":"Qiu L, Yang J, Wang H, Zhu Y, Wang Y, Wu Q. Expression of T-helper-associated cytokines in the serum of pituitary adenoma patients preoperatively and postperatively. Med Hypotheses. 2013;80(6):781\u20136. https:\/\/doi.org\/10.1016\/j.mehy.2013.03.011.","journal-title":"Med Hypotheses."},{"issue":"2","key":"9782_CR58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2265.1996.d01-1554.x","volume":"45","author":"VL Green","year":"1996","unstructured":"Green VL, Atkin SL, Speirs V, et al. Cytokine expression in human anterior pituitary adenomas. Clin Endocrinol (Oxf). 1996;45(2):179\u201385. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.d01-1554.x.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"9782_CR59","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1046\/j.1365-2249.1999.00766.x","volume":"115","author":"JF Viallard","year":"2001","unstructured":"Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 (IL-2, interferon-gamma (IFN-\u03b3)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 2001;115(1):189\u201395. https:\/\/doi.org\/10.1046\/j.1365-2249.1999.00766.x.","journal-title":"Clin Exp Immunol."},{"issue":"10","key":"9782_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11101605","volume":"11","author":"MD Ilie","year":"2019","unstructured":"Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The microenvironment of pituitary tumors-biological and therapeutic implications. Cancers (Basel). 2019;11(10):1\u201322. https:\/\/doi.org\/10.3390\/cancers11101605.","journal-title":"Cancers (Basel)."},{"issue":"5","key":"9782_CR61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1530\/eje.0.1490455","volume":"149","author":"J Thiele","year":"2003","unstructured":"Thiele J, Lohrer P, Schaaf L, et al. Functional in vitro studies on the role and regulation of interleukin-6 in human somatotroph pituitary adenomas. Eur J Endocrinol. 2003;149(5):455\u201361. https:\/\/doi.org\/10.1530\/eje.0.1490455.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"9782_CR62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/0006-291X(89)91528-3","volume":"164","author":"JF Bazan","year":"1989","unstructured":"Bazan JF. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor \u03b2-chain. Biochem Biophys Res Commun. 1989;164(2):788\u201395. https:\/\/doi.org\/10.1016\/0006-291X(89)91528-3.","journal-title":"Biochem Biophys Res Commun."},{"issue":"6","key":"9782_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1365-2265.1994.tb02502.x","volume":"40","author":"TH Jones","year":"1994","unstructured":"Jones TH. Interleukin-6 an endocrine cytokine. Clin Endocrinol (Oxf). 1994;40(6):703\u201313. https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02502.x.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"9782_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1749-6632.2008.03970.x","volume":"1153","author":"U Renner","year":"2009","unstructured":"Renner U, De Santana EC, Gerez J, et al. Intrapituitary expression and regulation of the gp130 cytokine interleukin-6 and its implication in pituitary physiology and pathophysiology. Ann N Y Acad Sci. 2009;1153:89\u201397. https:\/\/doi.org\/10.1111\/j.1749-6632.2008.03970.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"5","key":"9782_CR65","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0739-7240(98)00027-7","volume":"15","author":"U Renner","year":"1998","unstructured":"Renner U, Gloddek J, Pereda MP, Arzt E, Stalla GK. Regulation and role of intrapituitary IL-6 production by folliculostellate cells. Domest Anim Endocrinol. 1998;15(5):353\u201362. https:\/\/doi.org\/10.1016\/S0739-7240(98)00027-7.","journal-title":"Domest Anim Endocrinol."},{"issue":"5","key":"9782_CR66","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000245928","volume":"72","author":"MR Haedo","year":"2009","unstructured":"Haedo MR, Gerez J, Fuertes M, et al. Regulation of Pituitary Function by Cytokines. Horm Res Paediatr. 2009;72(5):266\u201374. https:\/\/doi.org\/10.1159\/000245928.","journal-title":"Horm Res Paediatr."},{"issue":"4","key":"9782_CR67","doi-asserted-by":"publisher","first-page":"R241","DOI":"10.1530\/JME-17-0026","volume":"58","author":"M Sapochnik","year":"2017","unstructured":"Sapochnik M, Fuertes M, Arzt E. Programmed cell senescence: role of IL-6 in the pituitary. J Mol Endocrinol. 2017;58(4):R241\u201353. https:\/\/doi.org\/10.1530\/JME-17-0026.","journal-title":"J Mol Endocrinol."},{"issue":"11","key":"9782_CR68","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/bf03401765","volume":"4","author":"N Takahashi","year":"1998","unstructured":"Takahashi N. Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1998;4(11):707\u201314. https:\/\/doi.org\/10.1007\/bf03401765.","journal-title":"Mol Med."},{"issue":"12","key":"9782_CR69","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/ERC-19-0327","volume":"26","author":"P Marques","year":"2019","unstructured":"Marques P, Barry S, Carlsen E, et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr Relat Cancer. 2019;26(12):853\u201365. https:\/\/doi.org\/10.1530\/ERC-19-0327.","journal-title":"Endocr Relat Cancer."},{"issue":"9","key":"9782_CR70","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1210\/jcem.84.9.6005","volume":"84","author":"LJ Hofland","year":"1999","unstructured":"Hofland LJ, de Herder WW, Waaijers M, et al. Interferon-\u03b1-2a Is a Potent Inhibitor of Hormone Secretion by Cultured Human Pituitary Adenomas. J Clin Endocrinol Metab. 1999;84(9):3336\u201343. https:\/\/doi.org\/10.1210\/jcem.84.9.6005.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"9782_CR71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1210\/endo.132.1.8419142","volume":"132","author":"E Arzt","year":"1993","unstructured":"Arzt E, Buric R, Stelzer G, et al. Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology. 1993;132(1):459\u201367. https:\/\/doi.org\/10.1210\/endo.132.1.8419142.","journal-title":"Endocrinology."},{"issue":"1","key":"9782_CR72","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1210\/jc.2009-1583","volume":"95","author":"I Lupi","year":"2010","unstructured":"Lupi I, Manetti L, Caturegli P, et al. Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab. 2010;95(1):289\u201396. https:\/\/doi.org\/10.1210\/jc.2009-1583.","journal-title":"J Clin Endocrinol Metab."},{"key":"9782_CR73","doi-asserted-by":"publisher","unstructured":"Horseman ND, Yu-Lee L-Y. Transcriptional Regulation by the Helix Bundle Peptide Hormones: Growth Hormone, Prolactin, and Hematopoietic Cytokines. Endocr Rev. 1994;15(5):627-649. https:\/\/doi.org\/10.1210\/edrv-15-5-627","DOI":"10.1210\/edrv-15-5-627"},{"issue":"6","key":"9782_CR74","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1568-9972(02)00081-2","volume":"1","author":"O Vera-Lastra","year":"2002","unstructured":"Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002;1(6):360\u20134. https:\/\/doi.org\/10.1016\/S1568-9972(02)00081-2.","journal-title":"Autoimmun Rev."},{"issue":"3","key":"9782_CR75","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.autrev.2007.11.018","volume":"7","author":"LJ Jara","year":"2008","unstructured":"Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun Rev. 2008;7(3):251\u20135. https:\/\/doi.org\/10.1016\/j.autrev.2007.11.018.","journal-title":"Autoimmun Rev."},{"issue":"1","key":"9782_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11102-005-5082-5","volume":"8","author":"A De Bellis","year":"2005","unstructured":"De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and Autoimmunity. Pituitary. 2005;8(1):25\u201330. https:\/\/doi.org\/10.1007\/s11102-005-5082-5.","journal-title":"Pituitary."},{"key":"9782_CR77","doi-asserted-by":"publisher","unstructured":"CHIKANZA IC. Prolactin and Neuroimmunomodulation: In Vitro and in Vivo Observations. Ann N Y Acad Sci. 1999;876(1 NEUROENDOCRIN):119-130. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb07629.x","DOI":"10.1111\/j.1749-6632.1999.tb07629.x"},{"issue":"1","key":"9782_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/tropej\/50.1.37","volume":"50","author":"G Kapur","year":"2004","unstructured":"Kapur G. Serum Prolactin in Celiac Disease. J Trop Pediatr. 2004;50(1):37\u201340. https:\/\/doi.org\/10.1093\/tropej\/50.1.37.","journal-title":"J Trop Pediatr."},{"issue":"6","key":"9782_CR79","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000126307","volume":"56","author":"M Clodi","year":"1992","unstructured":"Clodi M, Svoboda T, Kotzmann HR, et al. Effect of elevated serum prolactin concentrations on cytokine production and natural killer cell activity. Neuroendocrinology. 1992;56(6):775\u20139. https:\/\/doi.org\/10.1159\/000126307.","journal-title":"Neuroendocrinology."},{"issue":"52","key":"9782_CR80","doi-asserted-by":"publisher","first-page":"20834","DOI":"10.1073\/pnas.0808700106","volume":"105","author":"S Yu","year":"2008","unstructured":"Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT. Failure of T cell homing, reduced CD4\/CD8\u03b1\u03b1 intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci. 2008;105(52):20834\u20139. https:\/\/doi.org\/10.1073\/pnas.0808700106.","journal-title":"Proc Natl Acad Sci."},{"issue":"2","key":"9782_CR81","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.smim.2003.12.008","volume":"16","author":"L Adorini","year":"2004","unstructured":"Adorini L. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol. 2004;16(2):127\u201334. https:\/\/doi.org\/10.1016\/j.smim.2003.12.008.","journal-title":"Semin Immunol."},{"key":"9782_CR82","doi-asserted-by":"publisher","unstructured":"Aboelnaga MM, Abdullah N, El Shaer M. 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. Endocrine, Metab Immune Disord - Drug Targets. 2017;17(3). https:\/\/doi.org\/10.2174\/1871530317666170609103332","DOI":"10.2174\/1871530317666170609103332"},{"issue":"5","key":"9782_CR83","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/nu14050973","volume":"14","author":"V Guarnotta","year":"2022","unstructured":"Guarnotta V, Di Gaudio F, Giordano C. Vitamin D Deficiency in Cushing\u2019s Disease: Before and After Its Supplementation. Nutrients. 2022;14(5):973. https:\/\/doi.org\/10.3390\/nu14050973.","journal-title":"Nutrients."},{"key":"9782_CR84","doi-asserted-by":"publisher","unstructured":"Bugada D, Allegri M, Lavand\u2019homme P, De Kock M, Fanelli G. Inflammation-Based Scores: A New Method for Patient-Targeted Strategies and Improved Perioperative Outcome in Cancer Patients. Biomed Res Int. 2014;2014:1-11. https:\/\/doi.org\/10.1155\/2014\/142425","DOI":"10.1155\/2014\/142425"},{"issue":"3","key":"9782_CR85","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11102-020-01112-5","volume":"24","author":"P Marques","year":"2021","unstructured":"Marques P, de Vries F, Dekkers OM, et al. Pre-operative serum inflammation-based scores in patients with pituitary adenomas. Pituitary. 2021;24(3):334\u201350. https:\/\/doi.org\/10.1007\/s11102-020-01112-5.","journal-title":"Pituitary."},{"issue":"2","key":"9782_CR86","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/eje.1.01831","volume":"152","author":"M Sohmiya","year":"2005","unstructured":"Sohmiya M, Kanazawa I, Kato Y. Effect of recombinant human GH on circulating granulocyte colony-stimulating factor and neutrophils in patients with adult GH deficiency. Eur J Endocrinol. 2005;152(2):211\u20135. https:\/\/doi.org\/10.1530\/eje.1.01831.","journal-title":"Eur J Endocrinol."},{"key":"9782_CR87","doi-asserted-by":"publisher","unstructured":"Szyde\u0142ko J, Szyde\u0142ko\u2010Gorzkowicz M, Matyjaszek\u2010matuszek B. Neutrophil\u2010to\u2010lymphocyte, platelet\u2010to\u2010lymphocyte ratios, and systemic immune\u2010inflammation index as potential biomarkers of chronic inflammation in patients with newly diagnosed acromegaly: A single\u2010centre study. J Clin Med. 2021;10(17). https:\/\/doi.org\/10.3390\/jcm10173997","DOI":"10.3390\/jcm10173997"},{"issue":"2","key":"9782_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20(2):185\u2013204. https:\/\/doi.org\/10.1007\/s10456-017-9552-y.","journal-title":"Angiogenesis."},{"issue":"4","key":"9782_CR89","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocr Rev. 2004;25(4):581\u2013611. https:\/\/doi.org\/10.1210\/er.2003-0027.","journal-title":"Endocr Rev."},{"issue":"3","key":"9782_CR90","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/BF02738884","volume":"10","author":"RV Lloyd","year":"1999","unstructured":"Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol. 1999;10(3):229\u201335. https:\/\/doi.org\/10.1007\/BF02738884.","journal-title":"Endocr Pathol."},{"issue":"6","key":"9782_CR91","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s004280000373","volume":"438","author":"S Vidal","year":"2001","unstructured":"Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch. 2001;438(6):595\u2013602. https:\/\/doi.org\/10.1007\/s004280000373.","journal-title":"Virchows Arch."},{"issue":"3","key":"9782_CR92","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12022-010-9119-6","volume":"21","author":"C Cristina","year":"2010","unstructured":"Cristina C, Perez-Millan MI, Luque G, et al. VEGF and CD31 Association in Pituitary Adenomas. Endocr Pathol. 2010;21(3):154\u201360. https:\/\/doi.org\/10.1007\/s12022-010-9119-6.","journal-title":"Endocr Pathol."},{"issue":"10","key":"9782_CR93","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.humpath.2005.07.015","volume":"36","author":"M Niveiro","year":"2005","unstructured":"Niveiro M, Aranda FI, Peir\u00f3 G, Alenda C, Pic\u00f3 A. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol. 2005;36(10):1090\u20135. https:\/\/doi.org\/10.1016\/j.humpath.2005.07.015.","journal-title":"Hum Pathol."},{"issue":"7","key":"9782_CR94","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1167\/iovs.16-19285","volume":"57","author":"R Amato","year":"2016","unstructured":"Amato R, Biagioni M, Cammalleri M, Dal Monte M, Casini G. VEGF as a Survival Factor in Ex Vivo Models of Early Diabetic Retinopathy. Investig Opthalmology Vis Sci. 2016;57(7):3066. https:\/\/doi.org\/10.1167\/iovs.16-19285.","journal-title":"Investig Opthalmology Vis Sci."},{"key":"9782_CR95","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.phrs.2017.09.022","volume":"128","author":"R Amato","year":"2018","unstructured":"Amato R, Catalani E, Dal Monte M, et al. Autophagy-mediated neuroprotection induced by octreotide in an ex vivo model of early diabetic retinopathy. Pharmacol Res. 2018;128:167\u201378. https:\/\/doi.org\/10.1016\/j.phrs.2017.09.022.","journal-title":"Pharmacol Res."},{"issue":"3\u20134","key":"9782_CR96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2152\/jmi.52.151","volume":"52","author":"W Liu","year":"2005","unstructured":"Liu W, Matsumoto Y, Okada M, et al. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Investig. 2005;52(3\u20134):151\u20138. https:\/\/doi.org\/10.2152\/jmi.52.151.","journal-title":"J Med Investig."},{"issue":"1","key":"9782_CR97","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1210\/jcem.85.1.6248","volume":"85","author":"MP Pereda","year":"2000","unstructured":"Pereda MP, Ledda MF, Goldberg V, et al. High Levels of Matrix Metalloproteinases Regulate Proliferation and Hormone Secretion in Pituitary Cells1. J Clin Endocrinol Metab. 2000;85(1):263\u20139. https:\/\/doi.org\/10.1210\/jcem.85.1.6248.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"9782_CR98","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11102-022-01211-5","volume":"25","author":"P Marques","year":"2022","unstructured":"Marques P, Silva AL, L\u00f3pez-Presa D, Faria C, Bugalho MJ. The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary. 2022;25(3):363\u201382. https:\/\/doi.org\/10.1007\/s11102-022-01211-5.","journal-title":"Pituitary."},{"issue":"9","key":"9782_CR99","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.tem.2019.06.004","volume":"30","author":"S Chiloiro","year":"2019","unstructured":"Chiloiro S, Capoluongo ED, Tartaglione T, et al. The Changing Clinical Spectrum of Hypophysitis. Trends Endocrinol Metab. 2019;30(9):590\u2013602. https:\/\/doi.org\/10.1016\/j.tem.2019.06.004.","journal-title":"Trends Endocrinol Metab."},{"issue":"November","key":"9782_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.576027","volume":"11","author":"LS Lamb","year":"2020","unstructured":"Lamb LS, Sim HW, McCormack AI. Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne). 2020;11(November):1\u201310. https:\/\/doi.org\/10.3389\/fendo.2020.576027.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"9782_CR101","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/jpm10030088","volume":"10","author":"C Duhamel","year":"2020","unstructured":"Duhamel C, Ilie MD, Salle H, et al. Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. J Pers Med. 2020;10(3):88. https:\/\/doi.org\/10.3390\/jpm10030088.","journal-title":"J Pers Med."},{"key":"9782_CR102","doi-asserted-by":"publisher","unstructured":"Majd N, Waguespack SG, Janku F, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020;8(2):e001532. https:\/\/doi.org\/10.1136\/jitc-2020-001532","DOI":"10.1136\/jitc-2020-001532"},{"issue":"7","key":"9782_CR103","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/ERC-22-0037","volume":"29","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Vasiljevic A, Jouanneau E, Raverot G. Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocr Relat Cancer. 2022;29(7):415\u201326. https:\/\/doi.org\/10.1530\/ERC-22-0037.","journal-title":"Endocr Relat Cancer."},{"key":"9782_CR104","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac024","author":"M-D Ilie","year":"2022","unstructured":"Ilie M-D, Vasiljevic A, Bertolino P, Raverot G. Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Endocr Rev. 2022. https:\/\/doi.org\/10.1210\/endrev\/bnac024.","journal-title":"Endocr Rev."},{"issue":"1","key":"9782_CR105","doi-asserted-by":"publisher","first-page":"19373","DOI":"10.1038\/s41598-020-76555-8","volume":"10","author":"K Taniguchi-Ponciano","year":"2020","unstructured":"Taniguchi-Ponciano K, Andonegui-Elguera S, Pe\u00f1a-Mart\u00ednez E, et al. Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci Rep. 2020;10(1):19373. https:\/\/doi.org\/10.1038\/s41598-020-76555-8.","journal-title":"Sci Rep."},{"key":"9782_CR106","doi-asserted-by":"publisher","unstructured":"Yang Q, Wang Y, Zhang S, et al. Biomarker discovery for immunotherapy of pituitary adenomas: Enhanced robustness and prediction ability by modern computational tools. Int J Mol Sci. 2019;20(1). https:\/\/doi.org\/10.3390\/ijms20010151","DOI":"10.3390\/ijms20010151"},{"issue":"April","key":"9782_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2021.627117","volume":"12","author":"J Guo","year":"2021","unstructured":"Guo J, Fang Q, Liu Y, Xie W, Li C, Zhang Y. Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma. Front Genet. 2021;12(April):1\u201312. https:\/\/doi.org\/10.3389\/fgene.2021.627117.","journal-title":"Front Genet."},{"issue":"1","key":"9782_CR108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17(1):36. https:\/\/doi.org\/10.1186\/s12943-018-0801-5.","journal-title":"Mol Cancer."},{"issue":"4","key":"9782_CR109","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MED.0000000000000344","volume":"24","author":"A Ben-Shlomo","year":"2017","unstructured":"Ben-Shlomo A, Cooper O. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours. Curr Opin Endocrinol Diabetes Obes. 2017;24(4):301\u20135. https:\/\/doi.org\/10.1097\/MED.0000000000000344.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"2","key":"9782_CR110","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00949","volume":"12","author":"M Musat","year":"2005","unstructured":"Musat M. Enhanced protein kinase B\/Akt signalling in pituitary tumours. Endocr Relat Cancer. 2005;12(2):423\u201333. https:\/\/doi.org\/10.1677\/erc.1.00949.","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"9782_CR111","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.beem.2009.05.004","volume":"23","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):525\u201341. https:\/\/doi.org\/10.1016\/j.beem.2009.05.004.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"1","key":"9782_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12022-012-9230-y","volume":"24","author":"EA Sajjad","year":"2013","unstructured":"Sajjad EA, Zieli\u0144ski G, Maksymowicz M, Hutnik \u0141, Bednarczuk T, W\u0142odarski P. MTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. Endocr Pathol. 2013;24(1):11\u20139. https:\/\/doi.org\/10.1007\/s12022-012-9230-y.","journal-title":"Endocr Pathol."},{"issue":"3","key":"9782_CR113","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1677\/ERC-08-0269","volume":"16","author":"A Gorshtein","year":"2009","unstructured":"Gorshtein A, Rubinfeld H, Kendler E, et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer. 2009;16(3):1017\u201327. https:\/\/doi.org\/10.1677\/ERC-08-0269.","journal-title":"Endocr Relat Cancer."},{"issue":"6","key":"9782_CR114","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-15-0891","volume":"15","author":"M Chanal","year":"2016","unstructured":"Chanal M, Chevallier P, Raverot V, et al. Differential Effects of PI3K and Dual PI3K\/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Mol Cancer Ther. 2016;15(6):1261\u201370. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0891.","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"9782_CR115","doi-asserted-by":"publisher","first-page":"R331","DOI":"10.1530\/ERC-14-0188","volume":"21","author":"E Monsalves","year":"2014","unstructured":"Monsalves E, Juraschka K, Tateno T, et al. The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer. 2014;21(4):R331\u201344. https:\/\/doi.org\/10.1530\/ERC-14-0188.","journal-title":"Endocr Relat Cancer."},{"issue":"14","key":"9782_CR116","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-15-0288","volume":"21","author":"M Lee","year":"2015","unstructured":"Lee M, Wiedemann T, Gross C, et al. Targeting PI3K\/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015;21(14):3204\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0288.","journal-title":"Clin Cancer Res."},{"issue":"124","key":"9782_CR117","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","volume":"2019","author":"Y Wang","year":"2019","unstructured":"Wang Y, He Q, Meng X, et al. Apatinib (YN968D1) and Temozolomide in Recurrent Invasive Pituitary Adenoma: Case Report and Literature Review. World Neurosurg. 2019;2019(124):319\u201322. https:\/\/doi.org\/10.1016\/j.wneu.2018.12.174.","journal-title":"World Neurosurg."},{"issue":"8","key":"9782_CR118","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1210\/jc.2019-00432","volume":"104","author":"P Dutta","year":"2019","unstructured":"Dutta P, Reddy KS, Rai A, et al. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation-Positive Child. J Clin Endocrinol Metab. 2019;104(8):3539\u201344. https:\/\/doi.org\/10.1210\/jc.2019-00432.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"9782_CR119","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12020-018-1677-2","volume":"62","author":"C Pivonello","year":"2018","unstructured":"Pivonello C, Patalano R, Solari D, et al. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine. 2018;62(3):663\u201380. https:\/\/doi.org\/10.1007\/s12020-018-1677-2.","journal-title":"Endocrine."},{"key":"9782_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1871530321666210226152901","volume":"21","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, De Marinis L. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact on the Therapeutic Management? Endocrine, Metab Immune Disord - Drug Targets. 2021;21:1\u201315. https:\/\/doi.org\/10.2174\/1871530321666210226152901.","journal-title":"Endocrine, Metab Immune Disord - Drug Targets"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-022-09782-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T02:18:32Z","timestamp":1679105912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-022-09782-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["9782"],"URL":"https:\/\/doi.org\/10.1007\/s11154-022-09782-1","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"23 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC, LDM have served as investigator for clinical trials funded by Novartis, Pfizer, Ipsen and Crinetics. SC received research grants from Pfizer s.r.l. and Recordati Rare Disease. They are members of the Abvisory Board for Recordati. All fees and honoraria are paid to the host institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}